It's How Medicine Should Be®

Physician Profile


call (888) 352-RUSH for help arranging an appointment

Deborah A. Hall, MD, PhD

Patient Feedback
  • Neurology
Board Certification:
  • Neurology
Faculty Rank: Associate Professor
Medical or Graduate Education: Indiana University School of Medicine
Residency: University of Colorado - Internal Medicine
Fellowship: University of Colorado - Movement Disorders
Clinical Expertise:
  • Ataxia
  • Botulinum toxin injections
  • Chorea
  • Corticobasal degeneration
  • Dystonia
  • Movement disorders
  • Movement disorders, fragile X-associated
  • Multiple system atrophy
  • Myoclonus
  • Parkinsonism
  • Parkinson's disease
  • Progressive supranuclear palsy
  • Restless legs syndrome (RLS)
  • Tics
  • Tourette syndrome
  • Tremor
Research Interests:
  • Genetics and movement disorders
  • Fragile X-associated tremor/ataxia syndrome
  • Neuroepidemiology
  • Clinical trials in Parkinson's disease
  • Exercise in movement disorders
Google Map

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to Listings go back five years.

  1. Characterization and Early Detection of Balance Deficits in Fragile X Premutation Carriers With and Without Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS).
    O'Keefe JA, Robertson-Dick E, Dunn EJ, Li Y, Deng Y, Fiutko AN, Berry-Kravis E, Hall DA
    2015 Mar 13
  2. Fragile X gene expansions are not associated with dementia.
    Hall DA, Bennett DA, Filley CM, Shah RC, Kluger B, Ouyang B, Berry-Kravis E
    Neurobiol. Aging
    2014 May 2
  3. Implementation of a markerless motion analysis method to quantify hyperkinesis in males with fragile X syndrome.
    O'Keefe JA, Espinoza Orías AA, Khan H, Hall DA, Berry-Kravis E, Wimmer MA
    Gait Posture
    2014 Feb
  4. Parkinsonism in fragile X-associated tremor/ataxia syndrome (FXTAS): revisited.
    Niu YQ, Yang JC, Hall DA, Leehey MA, Tassone F, Olichney JM, Hagerman RJ, Zhang L
    Parkinsonism Relat. Disord.
    2014 Apr
  5. Emerging topics in FXTAS.
    Hall DA, Birch RC, Anheim M, Jønch AE, Pintado E, O'Keefe J, Trollor JN, Stebbins GT, Hagerman RJ, Fahn S, Berry-Kravis E, Leehey MA
    J Neurodev Disord
  6. New observations in the fragile X-associated tremor/ataxia syndrome (FXTAS) phenotype.
    Fraint A, Vittal P, Szewka A, Bernard B, Berry-Kravis E, Hall DA
    Front Genet
  7. In the Gray Zone in the Fragile X Gene: What are the Key Unanswered Clinical and Biological Questions?
    Hall DA
    Tremor Other Hyperkinet Mov (N Y)
  8. Clinical neurogenetics: fragile x-associated tremor/ataxia syndrome.
    Hall DA, O'Keefe JA
    Neurol Clin
    2013 Nov
  9. Intranuclear inclusions in a fragile X mosaic male.
    Pretto DI, Hunsaker MR, Cunningham CL, Greco CM, Hagerman RJ, Noctor SC, Hall DA, Hagerman PJ, Tassone F.
    Transl Neurodegener. 2013
    2013 May 21
    2(1):10. doi: 10.1186/2047-9158-2-10.
  10. Study in Parkinson Disease of Exercise (SPARX): Translating high-intensity exercise from animals to humans.
    Moore CG, Schenkman M, Kohrt WM, Delitto A, Hall DA, Corcos D.
    Contemp Clin Trials. 2013
    2013 Jun 14
    36(1):90-98. doi: 10.1016/j.cct.2013.06.002. [Epub ahead of print]
  11. Exercise for people in early- or mid-stage Parkinson disease: a 16-month randomized controlled trial.
    Schenkman M, Hall DA, Barón AE, Schwartz RS, Mettler P, Kohrt WM.
    Phys Ther. 2012
    2012 Nov
    92(11):1395-410. doi: 10.2522/ptj.20110472. Epub 2012 Jul 19.
  12. Fragile X-associated tremor ataxia syndrome in FMR1 gray zone allele carriers.
    Hall D, Tassone F, Klepitskaya O, Leehey M.
    Mov Disord. 2012
    2012 Feb
    27(2):296-300. doi: 10.1002/mds.24021. Epub 2011 Dec 11.
  13. Fragile x-associated tremor ataxia syndrome: the expanding clinical picture, pathophysiology, epidemiology, and update on treatment.
    Hall DA, O'keefe JA.
    Tremor Other Hyperkinet Mov (N Y). 2012
    2. doi:pii: tre-02-56-352-1. Epub 2012 May 11.
  14. Pragmatic communication is impaired in Parkinson disease.
    Hall D, Ouyang B, Lonnquist E, Newcombe J.
    Int J Neurosci. 2011
    2011 May
    121(5):254-6. doi: 10.3109/00207454.2010.550389. Epub 2011 Feb 25.
  15. Executive dysfunction in young FMR1 premutation carriers: forme fruste of FXTAS or new phenotype?
    Berry-Kravis E, Hall DA.
    Neurology. 2011
    2011 Aug 16
    77(7):612-3. doi: 10.1212/WNL.0b013e3182299f98. Epub 2011 Jul 20. No abstract available.
  16. FMR1 gray-zone alleles: association with Parkinson's disease in women?
    Hall DA, Berry-Kravis E, Zhang W, Tassone F, Spector E, Zerbe G, Hagerman PJ, Ouyang B, Leehey MA.
    Mov Disord. 2011
    2011 Aug 15
    26(10):1900-6. doi: 10.1002/mds.23755. Epub 2011 May 12.
  17. Improving fragile X-associated tremor/ataxia syndrome symptoms with memantine and venlafaxine.
    Ortigas MC, Bourgeois JA, Schneider A, Olichney J, Nguyen DV, Cogswell JB, Hall DA, Hagerman RJ.
    J Clin Psychopharmacol. 2010
    2010 Oct
    30(5):642-4. doi: 10.1097/JCP.0b013e3181f1d10a. No abstract available.
  18. Shoulder pain in Parkinson's disease: a case-control study.
    Madden MB, Hall DA.
    Mov Disord. 2010
    2010 Jun 15
    25(8):1105-6. doi: 10.1002/mds.23048. No abstract available.
  19. Parkinsonism and cognitive decline in a fragile X mosaic male.
    Hall D, Pickler L, Riley K, Tassone F, Hagerman R.
    Mov Disord. 2010
    2010 Jul 30
    25(10):1523-4. doi: 10.1002/mds.23150. No abstract available.
  20. Tremor in 48,XXYY syndrome.
    Tartaglia N, Borodyanskaya M, Hall DA.
    Mov Disord. 2009
    2009 Oct 15
    24(13):2001-7. doi: 10.1002/mds.22700. Erratum in: Mov Disord. 2010 Aug 15;25(11):1764. Borodyanskya, Mariya [corrected to Borodyanskaya, Mariya].
  21. Parkinsonism in FMR1 premutation carriers may be indistinguishable from Parkinson disease.
    Hall DA, Howard K, Hagerman R, Leehey MA.
    Parkinsonism Relat Disord. 2009
    2009 Feb
    15(2):156-9. doi: 10.1016/j.parkreldis.2008.04.037. Epub 2008 Jun 20.
  22. Movement disorders associated with aripiprazole use: a case series.
    Hall DA, Agarwal P, Griffith A, Segro V, Seeberger LC.
    Int J Neurosci. 2009
    119(12):2274-9. doi: 10.3109/00207450903225553.
  23. Persistent neurobehavioral signs and symptoms following West Nile fever.
    Hall DA, Tyler KL, Frey KL, Kozora E, Arciniegas DB.
    J Neuropsychiatry Clin Neurosci.
    2008 Winter
  24. Endurance exercise training to improve economy of movement of people with Parkinson disease: three case reports.
    Schenkman M, Hall D, Kumar R, Kohrt WM.
    Phys Ther.
    2008 Jan
  25. Cognitive profile of fragile X premutation carriers with and without fragile X-associated tremor/ataxia syndrome.
    Grigsby J, Brega AG, Engle K, Leehey MA, Hagerman RJ, Tassone F, Hessl D, Hagerman PJ, Cogswell JB, Bennett RE, Cook K, Hall DA, Bounds LS, Paulich MJ, Reynolds A.
    2008 Jan
  26. Adult-onset Alexander disease with progressive ataxia and palatal tremor.
    Howard KL, Hall DA, Moon M, Agarwal P, Newman E, Brenner M.
    Mov Disord.
    2008 Jan
  27. Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems
    Hagerman RJ, Hall DA, Coffey S, Leehey M, Bourgeois J, Gould J, Zhang L, Seritan A, Berry-Kravis E, Olichney J, Miller JW, Fong AL, Carpenter R, Bodine C, Gane LW, Rainin E, Hagerman H, Hagerman PJ
    Clin Interv Aging
  • (If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
  • View Transcript
Patient feedback information is available for physicians employed by Rush University Medical Center who have received 30 or more patient surveys. Responses are measured on a scale of 1 to 5, with 5 being the best score.
Number of Patient Surveys
Friendliness/courtesy of the care provider
Explanations the care provider gave you about your problem or condition
Concern the care provider showed for your questions or worries
Likelihood of your recommending this care provider to others
Care provider's efforts to include you in decisions about your treatment
Information the care provider gave you about medications
Instructions the care provider gave you about follow-up care
Your confidence in this care provider
Degree to which care provider talked with you using words you could understand
Amount of time the care provider spent with you
For more information about patient feedback, see the Quality Care section of the Rush University Medical Center website.